Michael R. Charlton, MD, MBBS, discusses the interaction between liver disease and hepatocellular carcinoma.
Michael R. Charlton, MD, MBBS
Advertisement
Articles by Michael R. Charlton, MD, MBBS
Michael R. Charlton, MD, MBBS, discusses the effects of the COVID-19 pandemic on hepatocellular carcinoma.
Michael R. Charlton, MD, MBBS, discusses the emergence of biomarkers in hepatocellular carcinoma.
Advertisement
Latest Updated Articles
Dr. Charlton on the Interaction Between Liver Disease and HCCPublished: June 16th 2021 | Updated:
Dr. Charlton on the Effects of the COVID-19 Pandemic on HCCPublished: April 20th 2021 | Updated:
Dr. Charlton on the Emergence of Biomarkers in HCCPublished: March 5th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
5